PolyPid (PYPD) The Citizens Life Sciences Conference 2026 summary

Regulatory and clinical progress

• NDA submission for D-PLEX₁₀₀ is imminent, with rolling submission to be completed within a few months and a PDUFA date expected around year-end or January.

• FDA pre-NDA meeting confirmed Phase 3 SHIELD I and Phase 2 data are sufficient for approval, with clear alignment on efficacy and safety.

• D-PLEX₁₀₀ holds Breakthrough Therapy Designation, enabling frequent FDA communication and eligibility for priority review.

• European regulatory submission is planned a few months after the FDA process is finalized.

Clinical data and product impact

• Phase 3 trial in open colorectal resection showed a 60% reduction in surgical site infection and 40% reduction in combined endpoint of mortality, reoperation, and infection, with robust statistical significance (p=0.0013).

• Secondary endpoints included reduced severity of infections (ASEPSIS score >20) by over 60% and consistent benefit in minimally invasive procedures.

• Product offers 30-day local antibiotic coverage, aiming to reduce hospital stays, costs, and delays in oncology protocols for cancer patients.

Market strategy and commercialization

• Initial label expected for colorectal surgery, with plans to expand to abdominal and other high-risk surgeries such as breast reconstruction and abdominoplasty.

• Target market includes 4.4 million abdominal surgeries annually in the U.S., with academic centers as primary early adopters.

• Market research and engagement with surgeons and pharmacy directors indicate likely adoption first in high-risk patients, with broader use anticipated.

• Preparation for launch includes education, pharmacoeconomic studies, and application for NTAP reimbursement.

• Seeking a commercial partner with strong hospital presence to support broad label expansion and distribution.